BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering, creating, testing and delivering transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. The Company's pipeline of development programs ranges from early science to advanced clinical trials that include Acoramidis (AG10), a next-generation small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of amyloidosis TTR (ATTR); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI), as a treatment option for children with achondroplasia; Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR) for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, an investigational, orally administered, small molecule substrate supplementation therapy that the Company is developing for the treatment of LGMD2I, also known as LGMDR9.

Employees

728

Sector

Pharmaceuticals

Calendar

Feb. 18 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
26-02-11	71.02 $	-1.99%	677,952
26-02-10	72.47 $	+0.25%	1,884,429
26-02-09	72.29 $	+6.23%	3,114,347
26-02-06	68.05 $	+6.78%	4,742,019
26-02-05	63.73 $	-15.24%	8,919,858

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

72.47USD

Average target price

93.30USD

Spread / Average Target

+28.74%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 01:20:28 2026-02-11 pm EST			5-day change	1st Jan Change
71.16 ^USD	-1.81%		-5.54%	-7.14%

Jan. 28	Barclays Initiates Coverage on BridgeBio Pharma With Overweight Rating, $157 Price Target	MT
Jan. 27	Intellia gets FDA nod to resume one gene therapy trial after safety pause	RE

Capitalization	13.97B 11.77B 10.77B 10.24B 18.98B 1,267B 19.62B 124B 49.6B 609B 52.38B 51.3B 2,141B	P/E ratio 2025 *	-21.1x	P/E ratio 2026 *	-42.9x
Enterprise value	15.1B 12.73B 11.65B 11.07B 20.52B 1,371B 21.22B 134B 53.63B 659B 56.64B 55.47B 2,315B	EV / Sales 2025 *	30.5x	EV / Sales 2026 *	16.6x
Free-Float	78.66%	Yield 2025 *	-	Yield 2026 *	-

Jan. 28	Barclays Initiates Coverage on BridgeBio Pharma With Overweight Rating, $157 Price Target	MT
Jan. 27	Intellia gets FDA nod to resume one gene therapy trial after safety pause	RE
Jan. 21	BridgeBio Pharma Inc issues $632.5 million convertible senior notes due 2033	RE
Jan. 16	BridgeBio Prices $550 Million Convertible Senior Notes Offering	MT
Jan. 14	BridgeBio Pharma Plans Offering of Senior Notes due 2033	MT
Jan. 14	BridgeBio continues long term debt management strategy and announces proposed offering of convertible senior notes	RE
Jan. 13	BridgeBio Pharma Insider Sold Shares Worth $6,043,168, According to a Recent SEC Filing	MT
Jan. 12	BridgeBio Pharma, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 07:30 AM
Jan. 12	BridgeBio Pharma reports Attruby product revenue $146 mln in Q4	RE
Jan. 09	BridgeBio Pharma, Inc. - Special Call
Jan. 06	BridgeBio Pharma Has 20% Upside Growth Potential, Morgan Stanley Says	MT
Jan. 06	Morgan Stanley Initiates BridgeBio Pharma at Overweight With $96 Price Target	MT
Dec. 17	BridgeBio Pharma Insider Sold Shares Worth $2,239,902, According to a Recent SEC Filing	MT

Jan. 28	Barclays Initiates Coverage on BridgeBio Pharma With Overweight Rating, $157 Price Target	MT
Jan. 06	BridgeBio Pharma Has 20% Upside Growth Potential, Morgan Stanley Says	MT
Jan. 06	Morgan Stanley Initiates BridgeBio Pharma at Overweight With $96 Price Target	MT
Dec. 11	Bernstein Initiates BridgeBio Pharma at Outperform With $94 Price Target	MT
Nov. 08	BridgeBio Pharma, Inc. Presents Data from the ATTRibute-CM Study	CI

BridgeBio Pharma, Inc. Stock

Equities

BBIO

US10806X1028

Pharmaceuticals

Valuation: BridgeBio Pharma, Inc.

Chart: BridgeBio Pharma, Inc.

Latest news: BridgeBio Pharma, Inc.

Last Transcript: BridgeBio Pharma, Inc.

Analysts' recommendations: BridgeBio Pharma, Inc.

Press Releases: BridgeBio Pharma, Inc.

News in other languages: BridgeBio Pharma, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: BridgeBio Pharma, Inc.

Biopharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Jan. 27	CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	GL
Jan. 16	BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027	GL
Jan. 14	BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027	GL
Jan. 12	BridgeBio Pharma : corporate presentation january 2026	PU
Jan. 12	BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference	GL

Jan. 15	USA-Les valeurs à suivre à Wall Street (actualisé)
25-10-30	Wall Street : Toujours debout, mais légèrement chancelant
25-10-27	MÄRKTE USA/Fest - Börsianer setzen auf Entspannung zwischen USA und China
25-10-27	MÄRKTE USA/Fest - Neue KI-Chips beflügeln Qualcomm
25-10-27	MÄRKTE USA/Rekordlauf geht weiter - Technologieaktien favorisiert

1 day	-1.76%
1 week	-5.54%
Current month	-8.08%
1 month	-7.57%
3 months	+6.68%
6 months	+47.23%
Current year	-7.14%

1 week	62.84	75.92
1 month	62.84	81.32
Current year	62.84	81.32
1 year	28.32	81.32
3 years	10.57	81.32
5 years	4.98	81.32
10 years	4.98	81.32

Manager	Title	Age	Since
Francis McCormick PRN	Corporate Officer/Principal	75	2019-03-31
Neil Kumar CEO	Chief Executive Officer	47	2015-03-31
Charles Homcy PRN	Corporate Officer/Principal	77	2019-01-31

Director	Title	Age	Since
Charles Homcy BRD	Director/Board Member	77	2018-10-31
Eric Aguiar BRD	Director/Board Member	64	2019-02-28
James Momtazee BRD	Director/Board Member	54	2016-02-29

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
BRIDGEBIO PHARMA, INC.	-1.81%	-5.54%	+128.23%	+512.81%	13.97B
REGENERON PHARMACEUTICALS, INC.	+2.80%	+0.13%	+16.62%	+1.58%	77.47B
CSL LIMITED	-4.64%	-8.24%	-39.54%	-46.41%	58.42B
UCB	-0.38%	-0.94%	+39.39%	+236.99%	59.92B
SAMSUNG BIOLOGICS CO.,LTD.	+0.12%	+71.20%	+71.20%	+71.20%	54.39B
BIOGEN INC.	+0.52%	+2.70%	+36.64%	-34.43%	27.74B
INCYTE CORPORATION	-1.68%	-3.91%	+48.63%	+23.11%	19.64B
INNOVENT BIOLOGICS, INC.	0.00%	+13.77%	+146.63%	+109.46%	19.9B
MODERNA, INC.	-5.24%	-7.18%	+28.34%	-76.85%	16.41B
SWEDISH ORPHAN BIOVITRUM AB	+2.10%	+13.90%	+27.56%	+66.95%	15.54B
Average	-0.82%	+3.15%	+50.37%	+86.44%	36.34B
Weighted average by Cap.	-0.46%	+1.57%	+35.18%	+66.33%

	2025 *	2026 *
Net sales	496M 418M 382M 363M 674M 44.98B 696M 4.41B 1.76B 21.63B 1.86B 1.82B 75.99B	906M 764M 699M 664M 1.23B 82.24B 1.27B 8.06B 3.22B 39.54B 3.4B 3.33B 139B
Net income	-675M -569M -521M -495M -917M -61.26B -948M -6B -2.4B -29.45B -2.53B -2.48B -103B	-345M -291M -266M -253M -469M -31.35B -485M -3.07B -1.23B -15.07B -1.3B -1.27B -52.96B
Net Debt	1.14B 957M 876M 833M 1.54B 103B 1.6B 10.1B 4.03B 49.57B 4.26B 4.17B 174B	1.07B 899M 823M 782M 1.45B 96.84B 1.5B 9.49B 3.79B 46.56B 4B 3.92B 164B